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Nine dominantly inherited neurodegenerative dis-
eases are caused by expansion of a CAG repeat en-
coding glutamine. An important development in the
study of such "polyglutamine" diseases was the reali-
zation thatmerely shutting off expression of a disease-
encoding transgene could arrest progression in ani-
mal models with significant disease pathology. Such
studies opened the door to a powerful new therapeutic
approach now being pioneered: silencing of the dom-
inant disease allele by RNA-mediated interference
(RNAi), for the arrest—and potential reversal—of the
disease process.
At least nine human neurodegenerative diseases are
caused by CAG repeat expansions that encode ex-
tended runs of the amino acid glutamine (Gusella and
MacDonald, 2000; Zoghbi and Orr, 2000). In addition to
Huntington’s disease (HD)—the most common and well-
known disorder of this group—dentatorubral-pallidoluy-
sian atrophy (DRPLA), spinobulbar muscular atrophy
(SBMA), and six spinocerebellar ataxias (SCA1, -2, -3,
-6, -7, and -17) comprise the polyglutamine (polyQ) dis-
eases. PolyQ disease patients display a range of neuro-
logical phenotypes, with most suffering from progres-
sive movement disorder and succumbing to disease
within 10–20 years of onset; they typically share the
same hallmark genetic mutation—expansion of a poly-
morphic polyQ repeat to beyond a threshold ofw37–40
glutamines. A fascinating aspect of the CAG/polyQ dis-
eases, as well as other dynamic repeat disorders, in-
cluding fragile X syndrome and myotonic dystrophy, is
the correlation between repeat size and disease sever-
ity, such that the longer the repeat, the earlier the onset
and more rapidly progressive the disease.
The expanded polyQ tract produces neuronal dys-
function and degeneration through abnormal protein in-
teractions elicited by the formation of misfolded con-
formers. Indeed, an important breakthrough in this
field was the observation that the mutant polyQ disease
protein accumulates, culminating in the formation of in-
clusions visible at the light-microscopic level. Ubiquiti-
nation, and incorporation of various chaperones and
proteasome components into these inclusions, likely re-
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chinery to efficiently turn over the protein (Muchowski
and Wacker, 2005; Sherman and Goldberg, 2001). Addi-
tional proteins, including transcription factors and core-
gulators, are localized to inclusions, suggesting that se-
questration of such cellular factors by the pathogenic
protein may lead to loss of these activities and contrib-
ute to disease. To date, the most potent modulators of
disease progression in animals have enhanced turnover
or solubility of the polyQ protein through upregulation of
chaperones, while other effective interventions have
compensated for various downstream effects, including
restoration of histone deacetylase activity (Di Prospero
and Fischbeck, 2005).
RNA-Mediated Interference:
The New Kid on the Block
Although such approaches offer promise, the most di-
rect solution to counter polyQ disease pathogenesis is
obvious: reduce expression of the mutant allele itself!
Two compelling in vivo studies strongly support the po-
tential success of such an approach (Yamamoto et al.,
2000; Zu et al., 2004). In both, the respective teams of in-
vestigators generated conditional transgenic mouse
models (one of HD and the other of SCA1) and demon-
strated that shutting off expression of the mutant trans-
gene dramatically slows disease progression and, for
select features, even reverses severe disease pathology.
In 1998, studies performed with double-stranded
RNAs in the nematode Caenorhabditis elegans revealed
a sequence-specific RNA-mediated pathway for turning
off gene expression (Zamore and Haley, 2005). The exis-
tence of this process, first observed in plants and now
known as RNA-mediated interference (RNAi), across vir-
tually all eukaryotic species soon became evident. Until
this discovery, effective, targeted, and long-lasting sup-
pression of a gene of interest was difficult and variable.
However, with the adaptation of RNAi for use in mam-
mals through the introduction of short-interfering RNAs
(siRNAs) and short-hairpin RNAs (shRNAs), the immense
potential of this technique as a therapeutic approach to
treat dominant diseases has become apparent.
Dramatic Effects in Polyglutamine Disease Models
Reveal RNAi’s Therapeutic Potential
As the polyQ diseases involve a dominant gain-of-func-
tion effect of the polyQ expansion tract, numerous trans-
genic mice have been generated by simply expressing
a human mutant protein in relevant neuronal populations
with heterologous promoters. Such polyQ models pro-
vide an outstanding testing ground for the feasibility of
the silencing approach: the first in vivo evaluation of
RNAi as a treatment for dominant neurodegenerative
disorders employed the very first polyQ disease mouse
model—the SCA1 transgenic mouse. In this study led by
the group of Beverly Davidson (Xia et al., 2004), a practi-
cal blueprint for the application of RNAi as a therapeutic
intervention was outlined. The strategy consisted of two
main parts. The first order of business was to identify an
optimal oligonucleotide for robust knock-down of the
target gene. As effective algorithms for oligonucleotide
design were not refined at the time, a screen of randomly
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in cell culture emerged a potent ataxin-1 shRNA for the
job. The second critical component of the RNAi thera-
peutic approach is mode of delivery. As the SCA1 trans-
genic mice display restricted expression of mutant
ataxin-1 to Purkinje cells (postmitotic neurons of the cer-
ebellum), the Davidson group evaluated adeno-associ-
ated virus serotype 1 (AAV1) for its ability to successfully
transduce these neurons. They then derived an AAV1
ataxin-1-shRNA construct, generated high-titer AAV
preparations, and injected the shRNA-expressing vi-
ruses into the cerebella of 7-week-old SCA1-82Q trans-
genic mice. The results were striking. They observed sig-
nificant improvements in treated mice within 2 months of
viral injection for motor coordination and Purkinje cell
neuropathology. Especially compelling was a dramatic
diminution in the accumulation of the pathogenic
ataxin-1 82Q protein in the nuclei of Purkinje cells from
transduced folia of treated mice.
Next, the Davidson group turned their attention to the
most common polyQ disease, HD (Harper et al., 2005).
The approach was similar—first identifying an effective
shRNA by screening candidates in cell culture cotrans-
fections and then confirming that AAV1 shRNAs injected
into striatum would infect those cells. They then pro-
ceeded to inject AAV1-huntingtin (htt) shRNAs into the
striata of 4-week-old HD transgenic mice. The N171-
82Q HD mouse model was selected because this trun-
cation fragment model contains enough of the htt read-
ing frame to permit targeting by a specific shRNA, and
the model displays a relatively rapid disease course,
reaching end stage by 5–6 months. In treated mice, dra-
matic reductions in soluble htt protein were observed as
rapidly as 2 weeks after viral injection, with reductions in
inclusions at end stage in the striatum and total elimina-
tion of cerebellar inclusions upon injection there. While
rotarod performance was nearly normalized in treated
mice, stride length improved but remained impaired rel-
ative to controls, indicating a less pronounced effect of
striatal delivery upon this behavioral trait. Striatal deliv-
ery did not prevent weight loss in treated HD mice,
and its effect upon survival was not measured. When
one considers the widespread expression pattern of
prion protein promoter driven htt in the N171-82Q
mice, however, the ability of striatal-delivered htt shRNA
to markedly improve two key motor deficits is remark-
ably encouraging.
Limitations and Challenges: Hurdles to Be Cleared
Before Going to the Clinic
While the SCA1 and HD studies highlight the enticing
therapeutic potential of RNAi, application of this strat-
egy to human patients may not be so straightforward.
An obvious difference between these mice and human
patients is that SCA1 and HD transgenic mice possess
two copies of the corresponding endogenous genes.
As RNAi knockdown was directed selectively to the hu-
man polyQ transgene in these experiments, simulta-
neous knockdown of the normal endogenous ortholog
of the disease gene was avoided. But in the human dis-
ease situation, the shRNAs being used would reduce ex-
pression of both the normal and disease alleles. Al-
though evidence for a dominant gain-of-function effect
with polyQ expansion is overwhelming, strong data
also suggest that a concomitant partial loss of normalfunction occurs for a number of polyQ disease proteins.
Notably, huntingtin may be involved in neurotrophic fac-
tor transcription or transport and/or may function in an
antiapoptotic capacity, with striatal neurodegeneration
occurring when expression is eliminated in mice postna-
tally (Dragatsis et al., 2000). Partial loss-of-function ac-
counts for androgen insensitivity in SBMA (Katsuno
et al., 2004), and suppression of ataxin-7 could have del-
eterious effects upon the transcription coactivator com-
plex to which it belongs (Palhan et al., 2005). Similarly,
normal ataxin-3 may play a role in mitigating accumula-
tion of misfolded proteins in polyQ and other neurode-
generative diseases (Warrick et al., 2005). Thus, while
elimination of select polyQ disease proteins in knockout
mice yields no dramatic untoward effects (such as
ataxin-1), knock-down of other polyQ disease proteins
could produce a whole other set of unacceptable
pathologies.
Although partial reduction of gene expression may be
well tolerated, an ideal solution to this problem would be
to target shRNA constructs selectively to the mutant
allele. As moderately long CAG tracts are present in nu-
merous genes, let alone in the normal allele correspond-
ing to the disease gene of interest, repeat-specific oligo-
nucleotides are not feasible. A plausible approach,
however, is to take advantage of occasional linked poly-
morphisms in the disease allele and to construct
shRNAs directed to those regions. Indeed, only a single
nucleotide polymorphism (SNP) is sufficient for allele-
specific targeting with RNAi. In SCA3, expanded CAG
repeat tracts are always followed by a cytosine in a
wide range of population groups, while a guanine typi-
cally follows the CAG repeat tract in normal alleles (Lim-
prasert et al., 1996). Consequently, many SCA3 patients
will possess versions of the ataxin-3 gene whose coding
regions will vary between the disease and normal alleles,
offering the prospect of allele-specific knock-down (Li
et al., 2004). Whether such common linked polymor-
phisms can be ferreted out for other polyQ disease loci
remains to be seen. However, as coding region SNPs
do occur with considerable frequency, one could envi-
sion haplotyping strategies aimed at the detection of
disease allele-specific SNPs on a patient-by-patient ba-
sis, followed by selection of the matching knock-down
construct from a set of validated shRNAs. It may be pos-
sible, for example, to design a set of 16 shRNA knock-
down constructs for a single locus in the hope that hap-
lotype screening of merely 8 SNPs per patient will yield
at least one disease allele-linked SNP to permit selective
targeting.
Even if these approaches prove problematic, global
deleterious effects could be circumvented by restricting
therapeutics to select cell types or brain structures cen-
tral to disease symptoms (e.g., cerebellum for the SCAs,
striatum for HD). Notably, in studies of RNAi targeting to
silence the pathogenic SCA1 transgene, disease pro-
gression was mitigated with only partial viral infection
of the cerebellum. Cell-type and region-specific treat-
ment could be a practical advantage of the RNAi ap-
proach, as widespread delivery may not be required
for marked improvement. On the other hand, this could
also be a limitation: if one can only treat select areas,
then degeneration in other regions may progress un-
abated. And as non-cell-autonomous degeneration
Minireview
717may be operating in a number of neurodegenerative dis-
ease processes including polyQ disorders, such restric-
tions could undermine therapeutic efficacy.
Critical for the success of the RNAi approach is the
availability of safe, precise, and robust methods of deliv-
ery to the central nervous system (CNS). Over the last
decade, significant advances in viral-vector develop-
ment and design have yielded promising options for
CNS treatment (Davidson and Breakefield, 2003), with
most of the non-cancer-related CNS gene therapy
work focused upon lentivirus and AAV. Recombinant
AAV has emerged as an appealing system for gene de-
livery due to development of improved vectors and pu-
rification systems, as well as the discovery of various se-
rotypes with high rates of infectivity. In the SCA1 and HD
work, the Davidson group selected AAV, as such viral
vectors can be maintained for many months in neurons
and tend not to integrate into the host genome—such in-
tegration, as occurs with lentivirus, could present added
problems of disrupting endogenous gene activity. One
important issue is host cell range, as the virus must suc-
cessfully infect the appropriate neurons, while another
issue is length of treatment. As AAV tends not to inte-
grate, but rather exists episomally, repeated treatment
may be required. The integration property of lentivirus
could be an advantage in this regard.
Other ingredients central to success include how to
control shRNA expression and which cells to target.
Once studies have established the least extensive host
cell range for therapeutic efficacy, promoters that drive
restrictive patterns of gene expression may be prefera-
ble, due to concern for off-target effects. Potential off-
target effects remain a serious issue for any shRNA ther-apy, as experience with RNAi as a therapeutic interven-
tion is limited to date. Conditional promoters—which
may be essential clinically for an approach as potentially
powerful as RNAi knockdown—would allow titration of
the extent of gene-silencing for exquisite control: mod-
est knock-down may be sufficient for less severe dis-
eases or early intervention, whereas more robust silenc-
ing might be required for advanced disease or later time
points. A drawback is that such promoters may present
their own risks by requiring expression of a foreign
transcriptional protein or long-term treatment with a reg-
ulator drug. There is also the issue of timing: RNAi knock-
down may be powerful at early stages, but once down-
stream events have played out, targeting the disease
gene itself may no longer be therapeutically beneficial.
Of course the ultimate stumbling block to successful im-
plementation of the RNAi approach for neurological dis-
eases is delivery. Hitting the target CNS region is by no
means trivial and will require stereotactic surgical proce-
dures and/or catheter placement, manipulations whose
success will depend upon the specific region being
targeted. Nonviral RNAi methods are also in develop-
ment (Dorsett and Tuschl, 2004), with similar issues of
delivery and specificity, although the use of osmotic
pumps with such approaches is particularly appealing
due to the ability to readily control the therapeutic (Vande
Velde and Cleveland, 2005). Ultimately, the clinical feasi-
bility of any RNAi therapy will hinge upon our ability to
overcome all of these issues.
Therapeutic Opportunities in Neurodegenerative
Disease Beyond PolyQ Disorders
The power of the RNAi approach is now being applied to
other neurological disorders, including amyotrophicFigure 1. RNAi Therapy for Dominant Neurological Disease: Polyglutamine Disorders as an Example
(A) Mutant protein, expressed from the mutant allele, bears an abnormally long polyQ domain, resulting in protein accumulation triggering a myr-
iad of deleterious events, culminating in neuronal dysfunction and loss. (B) Treatment with virus expressing shRNA selective for the mutant allele
knocks down levels of the mutant transcript, reducing mutant protein production and theoretically alleviating all resultant deleterious events.
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718lateral sclerosis (ALS) and Alzheimer’s disease (AD). The
vast majority of AD cases are sporadic—so what gene
do you target? A potentially ideal target is b-secretase
(BACE)—an enzyme that helps cleave amyloid precur-
sor protein (APP), contributing to amyloid plaque forma-
tion associated with degenerative changes. Complete
knock-out of BACE function in the brains of mice has
minimal effects, implying that targeting it with RNAi
should be highly tolerable. Recent results indicate that
intracerebral injection of BACE shRNA lentivirus vectors
into an APP transgenic mouse model of AD yielded re-
duced amyloid deposition in the hippocampus and neo-
cortex, with full recovery of spatial learning and memory
(Singer et al., 2005). In ALS, intramuscular delivery with
equine infectious anemia virus (EIAV) yielded an impres-
sive 80% extension in survival for the SOD1 mouse model
of inherited ALS1—the longest therapeutic mitigation to
date (Ralph et al., 2005), suggesting that this lentiviral de-
livery method may be promising for all motor neuron dis-
eases. Although application of RNAi to sporadic ALS
suffers from the lack of a clear target, extending the ap-
proach to sporadic Parkinson’s disease (PD) by target-
ing a-synuclein could be promising, because a-synu-
clein expression levels appear to directly correlate with
disease risk. Such work is likely already in progress.
Closing Thoughts
Despite the theoretical complications and practical
problems facing RNAi therapy for CNS disease, it is
now abundantly clear that the approach holds tremen-
dous promise. For polyQ diseases, one envisions that
the mutant protein is the trigger for an ever-increasing
cascade of diverse problems that affect a wide range
of fundamental cellular processes (Figure 1A). It is rea-
sonable to expect that maximal therapeutic benefit will
be achieved by directing treatment as close as possible
to the origin of the disease process—that is, close to ex-
pression of the mutant protein for such dominant neuro-
degenerative disorders (Figure 1B). A key question is:
can RNAi knock-down provide significant therapeutic
benefit after downstream deleterious effects have
been triggered? This is particularly crucial, because pa-
tients with most neurodegenerative diseases do not
present to clinic until significant underlying pathology al-
ready exists. In the case of the polyQ diseases, however,
there is a unique opportunity to circumvent this problem
for ‘‘presymptomatic’’ patients, as such at-risk individu-
als can be identified prior to disease onset with genetic
testing. For other patients, a combinatorial approach—
which hits multiple points from initiating events to down-
stream consequences—may prove most efficacious.
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